Today: 29 June 2026
Browse Category

NYSE:ZTS 4 November 2025 - 16 May 2026

Zoetis Drops to 52-Week Low, Monday Open in Focus

Zoetis Drops to 52-Week Low, Monday Open in Focus

Zoetis Inc. closed the week at a fresh 52-week low. Investors now head into the weekend weighing if the animal-health group’s post-earnings slide is done or set to move lower. The stock won’t see regular NYSE action until Monday. Heavy trading and new analyst target cuts have weighed on the name all week. The NYSE’s main session is 9:30 a.m. to 4:00 p.m. Eastern.
16 May 2026
··
Zoetis Stock Plunge: The Pet-Care Slowdown Wall Street Can’t Ignore

Zoetis Stock Plunge: The Pet-Care Slowdown Wall Street Can’t Ignore

Zoetis Inc. slashed its outlook for 2026 profit and revenue, following a first-quarter miss that caught Wall Street off guard—a notable setback for the animal-health firm known for riding premium pet drug demand. Shares slid after Zoetis pointed to U.S. pet owners pulling back on vet appointments and opting out of pricier care. Timing comes into play here. The company’s U.S. companion-animal segment—think treatments for dogs and cats—dropped 11% last quarter. Dermatology, Simparica Trio, Librela: all softer. Investors were counting on stable pricing in this area, not a sharp hit to demand.
8 May 2026
·
Zoetis (ZTS) Stock: What to Know Before the Market Opens on Dec. 26, 2025

Zoetis (ZTS) Stock: What to Know Before the Market Opens on Dec. 26, 2025

U.S. stocks return from the Christmas holiday pause with Zoetis Inc. back in focus—not because of an earnings report due today, but because December has brought a cluster of shareholder-return actions, product catalysts, and analyst resets that investors are still digesting heading into the next session. Keep one calendar detail in mind first: U.S. exchanges were closed on Thursday, Dec. 25, and Wednesday, Dec. 24 had an early close at 1:00 p.m. ET. That means many investors are coming into Friday’s session with fewer “fresh” price signals than usual, making recent headlines and forward expectations matter even more. New York Stock Exchange
26 December 2025
·
Zoetis Stock (ZTS) After Hours on Dec. 24, 2025: Price Action, Today’s Headlines, Analyst Forecasts, and What to Watch Before the Next Market Open

Zoetis Stock (ZTS) After Hours on Dec. 24, 2025: Price Action, Today’s Headlines, Analyst Forecasts, and What to Watch Before the Next Market Open

Zoetis Inc. wrapped up the Christmas Eve, holiday-shortened session with a solid gain—and then held steady in thin after-hours trading as investors headed into the U.S. market’s Christmas Day shutdown. After the bell on Wednesday, Dec. 24, 2025, ZTS was changing hands around $125.50 in extended trading, essentially flat after-hours, following a session that ended up about +1.6% on the day. MarketBeat+1
25 December 2025
·
Zoetis Stock (ZTS) News Today: $1.75B Convertible Notes, Accelerated Buybacks, Dividend Raise, and Analyst Forecasts (Dec. 17, 2025)

Zoetis Stock (ZTS) News Today: $1.75B Convertible Notes, Accelerated Buybacks, Dividend Raise, and Analyst Forecasts (Dec. 17, 2025)

Zoetis Inc. stock is back in focus on Wednesday, December 17, 2025, as investors weigh a fresh analyst update against a flurry of recent corporate actions—most notably a $1.75 billion convertible notes financing designed to fund substantial share repurchases, plus a dividend increase heading into 2026. MarketScreener+2investor.zoetis.com+2 Zoetis is the world’s largest pure-play animal health company, with a portfolio spanning companion animal and livestock medicines, vaccines, diagnostics, and technology. Business Wire+1
17 December 2025
··
Zoetis 2025: Animal Health Giant’s Latest Breakthroughs, Stock Outlook & Key Investor Insights

Zoetis 2025: Animal Health Giant’s Latest Breakthroughs, Stock Outlook & Key Investor Insights

Zoetis is the global frontrunner in animal health, offering a diverse portfolio for both companion animals and farm animals. The company’s products range from vaccines and parasiticides to dermatology treatments and high-tech diagnostics. This breadth has helped Zoetis capture the #1 industry position – in 2023 its $8.5B in sales exceeded the next-largest competitor by over 50%proclinical.comproclinical.com. Zoetis continues to leverage this scale and innovation engine in 2025, focusing on pet care growth while managing challenges in livestock. Recent 2025 highlights: The first half of 2025 saw Zoetis deliver solid growth. In Q1, revenue grew just 1% on a reported basis but a robust 9% on an organic basis once currency and divestitures were stripped outnews.zoetis.com. CEO Kristin Peck praised “our diversified portfolio across markets and species” and the strong demand for innovative pet products driving those resultsnews.zoetis.com. By Q2, reported growth improved to +4% and Zoetis raised its full-year outlook at the timemyvetcandy.commyvetcandy.com. Key growth drivers included blockbuster pet parasiticides, dermatology meds, and new monoclonal antibody pain therapies Librela® and Solensia®myvetcandy.commyvetcandy.com.
4 November 2025
··

Stock Market Today

  • SpaceX (SPCX) shares fade after IPO pop; attention turns to Nasdaq-100 inclusion
    June 29, 2026, 1:43 PM EDT. SpaceX (NASDAQ: SPCX) jumped as high as $225 from its $135 IPO, but slipped back to near $155. The company is still losing cash even with $4.7 billion Q1 2026 revenue. Some see index funds as forced buyers if SPCX gets added to the Nasdaq-100, which could bring new demand and help counter worries about valuation and the risk from lock-up expiry. Analysts point to SpaceX's strong position in launches and Starlink's global network, but note ongoing cash burn and no dividend. Some investors now look at the current price as a possible opportunity with index inclusion ahead as the next big event.
Go toTop